• Nicoleta Blebea Ovidius University of Constanta, Faculty of Pharmacy, Constanta
  • Gabriela Mitea Ovidius University of Constanta, Faculty of Pharmacy, Constanta



COVID-19, SARS-CoV-2, pandemic, treatment, vaccine


INTRODUCTION: Due to the rapid outbreak of the pandemic that causes SARS-CoV-2 infection and the increased rate of morbidity and mortality as a result of this new infection, the treatments pursued in therapy must have an increased potential to inhibit the replication of this virus.

OBJECTIVES: The main objective of this article was to describe the most current drug therapies and their mechanisms of action used in the treatment of COVID-19. In this article, we have collected the latest information and multilingual international scientific discoveries about the treatment of COVID-19.

RESULTS: Several compounds can be used to treat COVID-19 in order to reduce the duration of the disease and the rate of infection, to reduce the viral load, to prevent tissue damage, to stimulate the maturation of many cells, including immune cells in the human body and to reduce its severe symptoms. The most effective treatments were based on the antiviral drugs, antimalarial drugs, anti-inflammatory drugs, analgesics drugs, glycopeptide antibiotics, anticoagulants, vitamin C and vitamin D. The simplest and most direct approach to controlling SARS-CoV-2 outbreaks is the use of passive antibodies transferred from plasma to convalescent patients. Recently, studies have been completed for several vaccines that are approved against SARS-CoV-2.

CONCLUSION: Scientists around the world are collaborating and innovating to make tests, treatments and vaccines available to the public that will save lives collectively and end this pandemic.


Bischoff-F., H. A., Shao, A., Dawson-Hughes, B., Hathcock, J., Giovannucci, E., & Willett, W. C. (2010). Benefit-risk assessment of vitamin D supplementation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 21(7), 1121–1132.

Breining, P., Frølund, A. L., Højen, J. F., Gunst, J. D., Staerke, N. B., Saedder, E., Cases-Thomas, M., Little, P., Nielsen, L. P., Søgaard, O. S., & Kjolby, M. (2021). Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic & clinical pharmacology & toxicology, 128(2), 204–212.

Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., … Zhou, J. (2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology, 146(1), 137–146.e3.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., … Wang, C. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine, 382(19), 1787–1799.

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2021). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing.

Charoenngam, N., Shirvani, A., Kalajian, T. A., Song, A., & Holick, M. F. (2020). The Effect of Various Doses of Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-blinded, Dose-response Study. Anticancer research, 40(1), 551–556.

Colunga B., R., Berrill, M., & Marik, P. E. (2020). The antiviral properties of vitamin C. Expert review of anti-infective therapy, 18(2), 99–101.

Creech, C. B., Walker, S. C., & Samuels, R. J. (2021). SARS-CoV-2 Vaccines. JAMA, 325(13), 1318–1320.

Demsie, D. G., Gebre, A. K., Yimer, E. M., Alema, N. M., Araya, E. M., Bantie, A. T., Allene, M. D., Gebremedhin, H., Yehualaw, A., Tafere, C., Tadese, H. T., Amare, B., Weldekidan, E., & Gebrie, D. (2020). Glycopeptides as Potential Interventions for COVID-19. Biologics : targets & therapy, 14, 107–114.

Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K., Russell, F., Teh, B. W., & Wen, S. C. (2020). Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in immunology, 11, 579250.

Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019). JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford, England), 58(Suppl 1), i43–i54.

Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends, 14(1), 72–73.

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949.

Ghanbari, R., Teimoori, A., Sadeghi, A., Mohamadkhani, A., Rezasoltani, S., Asadi, E., Jouyban, A., & Sumner, S. C. J. (2020). Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiology, 15(18).

Grant, W. B., Lahore, H., McDonnell, S. L., Baggerly, C. A., French, C. B., Aliano, J. L., & Bhattoa, H. P. (2020). Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, 12(4), 988.

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, S. I., Kim, L., Tong, S., Lu, X., Lindstrom, S., Pallansch, M. A., … Washington State 2019-nCoV Case Investigation Team (2020). First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine, 382(10), 929–936.

Huang, D., Yu, H., Wang, T., Yang, H., Yao, R., & Liang, Z. (2021). Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of medical virology, 93(1), 481–490.

Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., … Ivachtchenko, A. V. (2020). AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ciaa1176. Advance online publication.

Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., Tapson, V., Iovine, N. M., Jain, M. K., Sweeney, D. A., El Sahly, H. M., Branche, A. R., Regalado Pineda, J., Lye, D. C., Sandkovsky, U., Luetkemeyer, A. F., … ACTT-2 Study Group Members (2021). Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine, 384(9), 795–807.

Keske, Ş., Tekin, S., Sait, B., İrkören, P., Kapmaz, M., Çimen, C., Uğur, S., Çelebi, İ., Bakır, V. O., Palaoğlu, E., Şentürk, E., Çağlayan, B., Çakar, N., Tabak, L., & Ergönül, Ö. (2020). Appropriate use of tocilizumab in COVID-19 infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 99, 338–343.

Klok, F. A., Kruip, M., van der Meer, N., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F., van Paassen, J., Stals, M., Huisman, M. V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-Thrombosis research, 191, 145–147.

Lei, G. S., Zhang, C., Cheng, B. H., & Lee, C. H. (2017). Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia. Antimicrobial agents and chemotherapy, 61(10), e01226-17.

Marineci C.D., Valeanu A., Negres S., Chirita C. (2021). Vaccination against COVID-19., 198, 7-16. /10.26416/Farm.198.1.2021.4353

Martineau, A. R., Jolliffe, D. A., Hooper, R. L., Greenberg, L., Aloia, J. F., Bergman, P., Dubnov-Raz, G., Esposito, S., Ganmaa, D., Ginde, A. A., Goodall, E. C., Grant, C. C., Griffiths, C. J., Janssens, W., Laaksi, I., Manaseki-Holland, S., Mauger, D., Murdoch, D. R., Neale, R., Rees, J. R., … Camargo, C. A., Jr (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ (Clinical research ed.), 356, i6583.

Mitea, G., Bucur, M., Dumitru, I. M., Rugina, S., & Bucur, L. (2020). Therapeutic options in SARS-CoV-2 infection., 195, 14-19.

Ravichandran, R., Purna, P., Vijayaragavan, S., Kalavakollu, R. T., Gaidhane, S., & Kumar, R. K. (2020). Efficacy and Safety of Indomethacin in Covid-19 patients. medRxiv

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England), 395(10223), e30–e31.

Rolain, J. M., Colson, P., & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International journal of antimicrobial agents, 30(4), 297–308.

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020). COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet. Infectious diseases, 20(4), 400–402.

Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal, 2, 69.

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(15), 732–739.

Yethindra, V., Tagaev, T., Uulu, M., S., & Parihar, Y. (2020). Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients. International Journal of Research in Pharmaceutical Sciences, 11(SPL1), 506-509.

Zhang, L., Yan, X., Fan, Q., Liu, H., Liu, X., Liu, Z., & Zhang, Z. (2020). D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of thrombosis and haemostasis : JTH, 18(6), 1324–1329.




How to Cite

Blebea, N. ., & Mitea, G. . (2021). THERAPEUTIC MANAGEMENT OF PATIENTS INFECTED WITH SARS-CoV-2 VIRUS - A REVIEW. Proceedings of CBU in Medicine and Pharmacy, 2, 9-16.